Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2014-02-18 | droxidopa | Chelsea Therapeutics (USA - NC) | neurogenic orthostatic hypotension (NOH). |
Granting of a Market Authorisation in the US |
2014-03-19 | miltefosine (hexadecylphosphocholine) | Paladin Therapeutics (Canada) | leishmaniasis |
Granting of a Market Authorisation in the US |
2014-06-09 | efinaconazole | Valeant Pharmaceuticals (Canada) | onychomycosis |
Granting of a Market Authorisation in the US |
2014-03-27 | 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Abbvie (USA - IL) | diffuse large B-cell lymphoma |
Granting of the orphan status in the US |
2015-01-07 | glutamic acid decarboxylase isoform 65 kDa | Diamyd Medical (Sweden) | type 1 diabetes |
Granting of a patent |
2014-12-17 | finafloxacin otic suspension | Alcon (USA - TX), a Novartis company (Switzerland) | acute otitis externa |
Granting of a Market Authorisation in the US |
2017-05-22 | 225Ac-lintuzumab | Actinium Pharmaceuticals (USA - NJ)/Voisin Consulting (France) | acute myelogenous leukemia | Granting of the orphan status in the EU |
2014-04-30 | 18-(p-[124I]-iodophenyl)octadecyl phosphocholine | Cellectar Biosciences (USA - WI) | diagnostic for the management of glioma |
Granting of the orphan status in the US |
2014-06-19 | human fully IgG1 antibody specific for CD33 | Boehringer Ingelheim (Germany) | acute myeloid leukemia |
Granting of the orphan status in the US |
2014-07-29 | Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E | Genentech, a member of the Roche Group (USA - Switzerland) | ovarian cancer |
Granting of the orphan status in the US |
2014-04-30 | demcizumab | OncoMed Pharmaceuticals (USA - CA) | pancreatic cancer |
Granting of the orphan status in the US |
2015-01-12 | ipatasertib | Genentech, a member of the Roche Group (USA - Switzerland) | gastric cancer including cancer of the gastro-esophageal junction |
Granting of the orphan status in the US |
2015-01-13 | liquid biopsy-based companion diagnostic that analyzes circulating nucleic acids obtained from blood samples | Qiagen (The Netherlands) AstraZeneca (UK) | non-small cell lung cancer (NSCLC) |
Granting of a Market Authorisation in the EU |
2015-01-07 | Qiagen (The Netherlands) | Product launch | ||
2014-12-30 | diclofenac sodium Injection | Hospira (USA -IL) | management of mild to moderate pain and for the management of moderate to severe pain alone or in combination with opioid analgesics |
Granting of a Market Authorisation in the US |
2015-01-09 | Roche (Switzerland) | detection and identification of HIV, HCV, and HBV in donations of human whole blood and blood components including source plasma |
Granting of a Market Authorisation in the US | |
2014-05-20 | recombinant human alpha-1-microglobulin | A1M Pharma (Sweden) | pre-eclampsia |
Granting of the orphan status in the EU |
2015-01-15 | long acting recombinant Factor VIIa-CTP3 | Prolor Biotech (Israel) | treatment and prophylaxis of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX |
Granting of the orphan status in the US |
2014-08-19 | recombinant human deoxyribonuclease I | SciVac (Israel) | treatment of graft-vs-host disease |
Granting of the orphan status in the US |
2014-08-18 | recombinant human deoxyribonuclease I | SciVac (Israel) | prevention of graft-vs-host disease |
Granting of the orphan status in the US |
© 2024 Biopharmanalyses - Powered by Samacom+